Value-Based Cancer Care Web Exclusives

October 2017

Adjuvant Ibandronate Does Not Improve Survival in HR-Positive Early Breast Cancer

Phoebe Starr

Breast Cancer

San Antonio, TX—The addition of the oral bisphosphonate ibandronate (Boniva) to endocrine therapy after surgery for hormone receptor (HR)-positive, early-stage breast cancer in early postmenopausal women did not significantly improve overall survival or disease-free survival (DFS), according to results of a study presented at the 2016 San Antonio Breast Cancer Symposium. [ Read More ]